Novo sows the seeds for a new heart failure approach

Despite the existence of various heart failure drugs there is no cure for the condition. Novo Nordisk hopes to change that with HS-001, a cell therapy it is developing alongside the Japanese company Heartseed and which recently went into first-in-human trials.